Date: 2015-02-13
Type of information: Nomination
Compound:
Company: DBV Technologies (France)
Therapeutic area: Allergic diseases - Immunological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 13, 2015, DBV Technologie, a clinical-stage specialty biopharmaceutical company, announced the appointment of Dr Jacques-Pierre Moreau to its Scientific Advisory Board. Dr Moreau has broad industry experience across the spectrum of drug discovery, development and commercialization. He has published over 50 articles in scientific journals and is named inventor or co-inventor in over 40 U.S. issued patents. He has been founder or co-founder of successful biotechs such as Biomeasure, Inc. (MA, U.S.A.), Kinerton, Ltd. (Ireland), ProteoThera (MA, U.S.A.) and Mulleris Therapeutics (MA, U.S.A.). Dr. Moreau is the former Chief Scientific Officer and Executive Vice-President for Ipsen SA (France). Active contributor to Ipsen’s IPO in 2005 and to the spin-offs of Preglem (CH), Radius Health, Inc. (MA, U.S.A.), Functional Therapeutics (U.K./CH) and Rhythm Pharmaceuticals (MA, U.S.A.). Dr. Moreau is a Director of Dr. Reddy’s Laboratories Ltd (India), member of the Science, Technology, Strategy and Risk committees. He is also former board member of Phytochemics, an Inventage Venture-funded company, former advisor for Nitto Denko & Teijin Pharmaceutical (Japan) and current advisor for Genosys (U.S.A.), and Banque Oddo (France). Dr. J Moreau holds a master’s degree in physical chemistry and was awarded a D.Sc from the University of Orleans, France based on doctoral studies conducted at the Worcester Foundation for Experimental Biology (now part of U-Mass), followed by post-doctoral studies at the École Polytechnique in Paris.
Financial terms:
Latest news:
